Pharvaris N.V. (PHVS) catalysts

Upcoming FDA decisions and readouts we track for Pharvaris N.V., each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 1 Rows last checked — 11 Sep 2026

FreeBioList tracks 1 upcoming catalyst for Pharvaris N.V. (PHVS, listed on Nasdaq). It concerns Deucrictibant IR (Hereditary angioedema, on-demand treatment).

First on the list: the PDUFA date for Deucrictibant IR (Hereditary angioedema, on-demand treatment), dated 23 Apr 2027.

The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 11 Sep 2026. The methodology page explains each status.

Background reading: What a PDUFA date is, and why the FDA doesn't publish them.

Ticker: PHVS
Next catalyst: 23 Apr 2027
Type: PDUFA date
Listed options: Yes

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
Pharvaris N.V. PHVS · Nasdaq	Deucrictibant IR	Hereditary angioedema, on-demand treatment	23 Apr 2027 in 198d	PDUFA date	Verified	6-K exhibit 99.2 ↗	Yes
Notes — Filing states the NDA "is currently under review with the FDA with a Prescription Drug User Fee Act (PDUFA) target action date of April 23, 2027." Source: 6-K exhibit 99.2, filed 12 Aug 2026 · verified 11 Sep 2026

Companies working on related conditions

Intellia Therapeutics (NTLA)Hereditary angioedema (HAE)

Also due in Q2 2027

Axsome Therapeutics (AXSM)PDUFA date for AXS-12 (reboxetine), 01 May 2027
Immunome (IMNM)PDUFA date for Varegacestat, 28 Apr 2027
Harmony Biosciences Holdings (HRMY)PDUFA date for Pitolisant GR, 01 Apr 2027
Zenas BioPharma (ZBIO)PDUFA date for Obexelimab, 27 May 2027
Context Therapeutics (CNTX)Phase 1 readout for CTIM-76, Q2 2027